Agalimmune established to develop innovative immunotherapeutics for treatment of cancer Agalimmune Ltd, a biopharmaceutical company, has been intended to develop innovative immunotherapeutics for the treating cancer, with a focus on solid tumours. The brand new company has been founded by an investment group comprising Loxbridge Research Animatrix and LLP Capital LLP. Agalimmune is based both in London and California www.med-drugs.com . The funding will be used to continue the translation of Agalimmune's leading immunotherapeutic technology, AlphajectTM, licensed from the University of Massachusetts Medical College , to the clinic.
A research content published on October 7, 2009 in the Globe Journal of Gastroenterology addresses this question. The research group led by Dr. Hsieh from Department of Medical procedures, Chang Gung Memorial Hospital-Chiayi, utilized the Cox proportional hazard model to analyze risk factors for failure of TIVAD and log-rank test to compare actuarial survival rates. Infection, thrombosis, and surgical complication rates are compared among the risk factors. A complete of 1348 totally implantable venous access gadgets were implanted in to the 1280 cancer individuals in this cohort research. In this study, the researchers find that increasing age, male gender, open-ended catheter and hematogenous malignancy were significant risk factors reducing survival of TIVADs by multivariate evaluation.